Jonathan Schechter bought $48k of PMCB
director at PharmaCyte Biotech, Inc.. 60,000 shares at an average of $0.80, traded Jan 5, 2026, filed Jan 7, 2026.
Score components
- +15RoleDirector
- +7Trade size$48k at market
- +6Relative to holdingsHoldings up 45%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.7%, 3m -17.9%, 6m -14.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001683168-26-000147, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | POpen-market purchase Common Stock | +20,000 | $0.78 | $16k | 152,500 | Jan 7, 2026 |
| Jan 6, 2026 | POpen-market purchase Common Stock | +20,000 | $0.79 | $16k | 172,500 | Jan 7, 2026 |
| Jan 7, 2026 | POpen-market purchase Common Stock | +20,000 | $0.84 | $17k | 192,500 | Jan 7, 2026 |
Related signals
Other insiders at PharmaCyte Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | PharmaCyte Biotech, Inc. | Joshua Silverman CEO and President | $80k 100,000 shares | +32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.